Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Fingolimod
Treatment for Multiple sclerosis
Typical Dosage: 0.5mg oral once daily
Effectiveness
85%
Safety Score
38%
Clinical Trials
101
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
38
DangerousModerateSafe
Treatment Details
Dosage Range
0.5mg oral once daily
Time to Effect
1-2 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
17(Treat 17 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$85,000
Monitoring:$4,000
Side Effect Mgmt:$1,500
Total Annual:$90,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$113,125
Cost per Remission
$258,571.43
Comparison vs Interferon Beta-1a
Cost Difference
+$25,500/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Fingolimod in Multiple sclerosis
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
NCT04480853RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Kaohsiung City, Taiwan +5 more
Started: Oct 12, 2020
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT04926818ACTIVE NOT RECRUITINGPHASE3
129 participants
INTERVENTIONAL
Little Rock, United States +50 more
Started: Oct 5, 2021
Completed Clinical Trials
15 completed trials for Fingolimod in Multiple sclerosis
The Gilenya Pregnancy Registry
NCT01285479COMPLETED
312 participants
OBSERVATIONAL
Fort Lauderdale, United States +60 more
Started: Oct 15, 2011
An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
NCT00670449COMPLETEDPHASE2
143 participants
INTERVENTIONAL
Chiba, Japan +19 more
Started: Apr 1, 2008
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT00662649COMPLETEDPHASE3
920 participants
INTERVENTIONAL
Chatswood, Australia +102 more
Started: Feb 1, 2008
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT01497262COMPLETEDPHASE3
162 participants
INTERVENTIONAL
Caba, Argentina +28 more
Started: Feb 1, 2012
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
NCT02232061COMPLETEDPHASE4
6 participants
INTERVENTIONAL
Ghent, Belgium +3 more
Started: Sep 29, 2014
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT00355134COMPLETEDPHASE3
1.08K participants
INTERVENTIONAL
Birmingham, United States +111 more
Started: Jun 1, 2006
Impact of Fingolimod Adherence on Outcomes
NCT05141669COMPLETED
694 participants
OBSERVATIONAL
East Hanover, United States
Started: May 18, 2020
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
NCT01281657COMPLETED
64 participants
OBSERVATIONAL
Cullman, United States +57 more
Started: Feb 1, 2011
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
NCT02225977COMPLETED
125 participants
OBSERVATIONAL
Los Angeles, United States
Started: Jul 31, 2013
Fingolimod Effect on Cytokine and Chemokine Levels
NCT02373098COMPLETEDPHASE4
126 participants
INTERVENTIONAL
Mecidiyeköy, Turkey (Türkiye) +2 more
Started: Mar 31, 2015
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
NCT03257358COMPLETEDPHASE4
382 participants
INTERVENTIONAL
Birmingham, United States +65 more
Started: Sep 19, 2017
Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
NCT02137707COMPLETED
135 participants
OBSERVATIONAL
Vancouver, Canada +5 more
Started: Nov 1, 2012
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
NCT01585298COMPLETEDPHASE4
7K participants
INTERVENTIONAL
Ostfildern, Germany +257 more
Started: Apr 29, 2012
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
NCT01578330COMPLETEDPHASE4
42 participants
INTERVENTIONAL
Ankara, Turkey (Türkiye) +10 more
Started: Oct 1, 2012
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
NCT01201356COMPLETEDPHASE3
4.13K participants
INTERVENTIONAL
Cullman, United States +457 more
Started: Sep 13, 2010
Showing 20 of 102 total trials